US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Therapeutics

25.82

-0.0700-0.27%

Volume:55.32K

Turnover:1.45M

Market Cap:711.16M

PE:-11.04

High:26.77

Open:25.89

Low:25.47

Close:25.89

Loading ...

Overview Company News Filings

AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline

Bicycle Therapeutics price target lowered to $15 from $40 at Barclays

Design Therapeutics Says Eye Drops for Fuchs Endothelial Corneal Dystrophy 'Well-Tolerated'

MT Newswires Live

Bicycle Therapeutics: Promising Advancements and Strong Financial Position Justify Buy Rating

Promising Developments in Gain Therapeutics’ GT-02287 Drive Buy Rating

Trevi Therapeutics management to meet virtually with B. Riley

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

Press Release: Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology

EXCLUSIVE: TransCode Therapeutics Reports Progress In Early-Stage Study For Lead Cancer Drug

Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Press Release: Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025

Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

Bicycle Therapeutics Q1 EPS $(0.88) Misses $(0.86) Estimate, Collaboration Revenue $9.98M Beat $7.78M Estimate

Gain Therapeutics to Participate at The Citizens Life Sciences Conference

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

Press Release: Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Press Release: Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LENZ/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":25.82,"timestamp":1746642359434,"preClose":25.89,"halted":0,"volume":55318,"delay":0,"floatShares":11211113,"shares":27543120,"eps":-2.338654,"marketStatus":"Trading","change":-0.07,"latestTime":"05-07 14:26:26 EDT","open":25.89,"high":26.765,"low":25.47,"amount":1450223.32616,"amplitude":0.050019,"askPrice":25.88,"askSize":203,"bidPrice":25.77,"bidSize":401,"shortable":0,"etf":0,"ttmEps":-2.338654,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746648000000},"marketStatusCode":2,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":25.89,"preHourTrading":{"tag":"盘前","latestPrice":26.4,"preClose":25.89,"latestTime":"09:27 EDT","volume":125,"amount":3250.6400000000003,"timestamp":1746624443607},"postHourTrading":{"tag":"盘后","latestPrice":25.89,"preClose":25.89,"latestTime":"17:04 EDT","volume":348986,"amount":9035269.48,"timestamp":1746565470524},"volumeRatio":0.251833,"impliedVol":0.2738,"impliedVolPercentile":0.25},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":11211113,"roa":"-25.64%","roe":"-38.94%","lyrEps":-2.338654,"volumeRatio":0.251833,"shares":27543120,"dividePrice":0,"high":26.765,"amplitude":0.050019,"preClose":25.89,"low":25.47,"week52Low":14.42,"pbRate":"3.48","week52High":38.93,"institutionHeld":0,"latestPrice":25.82,"committee":0.327815,"eps":-2.338654,"divideRate":0,"volume":55318,"delay":0,"ttmEps":-2.338654,"open":25.89,"prevYearClose":28.87,"prevWeekClose":29.52,"prevMonthClose":28.515,"prevQuarterClose":25.71,"fiveDayClose":28.515,"twentyDayClose":18.32,"sixtyDayClose":25},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532512839","title":"AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2532512839","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532512839?lang=en_us&edition=fundamental","pubTime":"2025-05-02 04:00","pubTimestamp":1746129600,"startTime":"0","endTime":"0","summary":"EBO-301 truncated Phase 3 study  misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2 study, patients had underlying severe, advanced MAC lung disease. Extensive enabling NTM data provides potential path forward in M. abscessus lung disease. Company focus remains centered on boron chemistry pipeline with initiation of high impact clinical programs in infectious diseases and an emerging oncology portfolio. Initiated start up activities for Phase 1 first in human study in healthy volunteers of AN2-502998, under development to treat chronic Chagas disease. Topline data for standard-of-care melioidosis observational trial expected in 2Q25; Phase 2 study planned for 2H25 with goal of reducing mortality from observed rates approaching 40%. First oncology compound from boron chemistry platform on track to advance into development in 2H25; targets best-in-class profiles with fully owned IP; novel oncology compounds target ENPP1, PI3Kα and other undisclosed t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/an2-therapeutics-reports-data-phase-200000802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4007","BK4139","ANTX"],"gpt_icon":0},{"id":"2532867488","title":"Bicycle Therapeutics price target lowered to $15 from $40 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2532867488","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532867488?lang=en_us&edition=fundamental","pubTime":"2025-05-02 02:01","pubTimestamp":1746122462,"startTime":"0","endTime":"0","summary":"Barclays lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $15 from $40 and keeps an Overweight rating on the shares following the ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicycle-therapeutics-price-target-lowered-to-15-from-40-at-barclays?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicycle-therapeutics-price-target-lowered-to-15-from-40-at-barclays?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2532888223","title":"Design Therapeutics Says Eye Drops for Fuchs Endothelial Corneal Dystrophy 'Well-Tolerated'","url":"https://stock-news.laohu8.com/highlight/detail?id=2532888223","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532888223?lang=en_us&edition=fundamental","pubTime":"2025-05-02 00:29","pubTimestamp":1746116981,"startTime":"0","endTime":"0","summary":"Design Therapeutics  said Thursday its experimental DT-168 eye drops to potentially treat Fuchs endothelial corneal dystrophy were well-tolerated in a phase 1 trial.The company said no serious side effects nor eye-related issues were reported. No treatment was discontinued due to adverse side effects, Design added.The company said it expects to begin a phase 2 biomarker trial in patients with Fuchs endothelial corneal dystrophy in H2, with results anticipated in 2026.The study will enroll FECD patients scheduled for corneal transplant surgery, the company added.Shares of the company were down 3.3% in recent trading.Price: 4.70, Change: -0.16, Percent Change: -3.29","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4505","BK4539","LENZ","BK4139","BK4007","DSGN"],"gpt_icon":0},{"id":"2532000177","title":"Bicycle Therapeutics: Promising Advancements and Strong Financial Position Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2532000177","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532000177?lang=en_us&edition=fundamental","pubTime":"2025-05-02 00:15","pubTimestamp":1746116124,"startTime":"0","endTime":"0","summary":"Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Bicycle Therapeutics (BCYC – Research Report) and keeping the price ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/bicycle-therapeutics-promising-advancements-and-strong-financial-position-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/bicycle-therapeutics-promising-advancements-and-strong-financial-position-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2532002303","title":"Promising Developments in Gain Therapeutics’ GT-02287 Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2532002303","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532002303?lang=en_us&edition=fundamental","pubTime":"2025-05-01 23:35","pubTimestamp":1746113717,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Gain Therapeutics (GANX – Research Report), with a price...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-developments-in-gain-therapeutics-gt-02287-drive-buy-rating-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-developments-in-gain-therapeutics-gt-02287-drive-buy-rating-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GT","GANX","LENZ"],"gpt_icon":0},{"id":"2532001943","title":"Trevi Therapeutics management to meet virtually with B. Riley","url":"https://stock-news.laohu8.com/highlight/detail?id=2532001943","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532001943?lang=en_us&edition=fundamental","pubTime":"2025-05-01 23:01","pubTimestamp":1746111660,"startTime":"0","endTime":"0","summary":"Virtual Meeting to be held on May 7 hosted by B. Riley. Published first on TheFly – the ultimate source for real-time, market-moving breaking finan...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/trevi-therapeutics-management-to-meet-virtually-with-b-riley-6?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/trevi-therapeutics-management-to-meet-virtually-with-b-riley-6?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4007","RILY","BK4127","IE00B19Z4B17.USD","IE00B66KJ199.SGD","IE00B7SZL793.SGD","IE0031619046.USD"],"gpt_icon":0},{"id":"2532089900","title":"TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2532089900","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532089900?lang=en_us&edition=fundamental","pubTime":"2025-05-01 21:01","pubTimestamp":1746104460,"startTime":"0","endTime":"0","summary":"A total of 13 patients treated with four escalating doses of TTX-MC138. Two patients have so far maintained stable disease on treatment for at least seven months. PD analysis at 24 hours post-dosing provides evidence of miR-10b target engagement. BOSTON, May 1, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. , the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced further progress in its Phase 1a clinical trial of TTX-MC138 in patients with metastatic cancer. TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit microRNA-10b, or miR-10b, a microRNA widely believed to be critical to the emergence and progression of many metastatic cancers. To date, 13 patients have received at least one dose of TTX-MC138 at 4 separate dose levels ranging from 0.8 mg/kg to 4.8 mg/kg. Two patients have been treated in the expanded enrollment.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/transcode-therapeutics-reports-further-progress-130100781.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/transcode-therapeutics-reports-further-progress-130100781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","BK4007","LU2065732104.USD","LENZ","BK4539","RNAZ","BK4139","PRGS"],"gpt_icon":0},{"id":"2532723770","title":"Press Release: Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2532723770","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532723770?lang=en_us&edition=fundamental","pubTime":"2025-05-01 20:45","pubTimestamp":1746103500,"startTime":"0","endTime":"0","summary":"Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products. Successful track record across oncology therapeutics including ADCs and antibody therapies ranging from early discovery to pre-clinical/clinical stage. 25+ year-career experience bolsters Company's efforts to address growing, high-value ADC market and maximize opportunities for non-dilutive capital. BOSTON and LONDON, May 01, 2025  -- Akari Therapeutics, Plc , an oncology biotechnology company developing novel payload antibody drug conjugates , today announced the appointment of Mark F. Kubik as Head of Business Development - Oncology.Mr. Kubik joins Akari from having most recently served as Senior Vice President, U.S and EU Business Development at I-MAB Biopharma where he was responsible for business development, alliance management and product / portfolio planning directed toward the US and EU business and operating spheres. Prior to that, he held leade","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4588","SG9999013999.USD","SG9999002224.SGD","LU0321505439.SGD","SG9999001176.USD","LU0306806265.USD","BK4022","IE00BBT3K403.USD","BK4599","SG9999001176.SGD","AKTX","IE00BLSP4452.SGD","BK4534","IE00B19Z3581.USD","SG9999002232.USD","BK4007","LU0868494617.USD","LU0170899867.USD","LU0225284248.USD","LU0234572021.USD","IE0002270589.USD","LU0456855351.SGD","LU1883839398.USD","R","IE00B19Z3B42.SGD","BK4139","SG9999003800.SGD","LU1894683348.USD","LU0122379950.USD","LU0058720904.USD","LU1894683264.USD","SG9999011175.SGD","LU1057294990.SGD","BK4232","IE000M9KFDE8.USD","IE00BLSP4239.USD","BK4550","LU0306807586.USD","LU0289739699.SGD","LU0985481810.HKD","BK4581","LU0321505868.SGD","BK4592","SGXZ57979304.SGD","BK4585","LENZ","LU1023059063.AUD","LU0225771236.USD"],"gpt_icon":1},{"id":"2532907735","title":"EXCLUSIVE: TransCode Therapeutics Reports Progress In Early-Stage Study For Lead Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2532907735","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532907735?lang=en_us&edition=fundamental","pubTime":"2025-05-01 20:32","pubTimestamp":1746102750,"startTime":"0","endTime":"0","summary":"TransCode Therapeutics, Inc.  announced further progress on Thursday in its Phase 1a clinical trial of TTX-MC138 in patients with metastatic cancer.To date, 13 patients have received at least one dose of TTX-MC138 at four separate dose levels ranging from 0.8 mg/kg to 4.8 mg/kg. Two patients have been treated in the expanded enrollment.Eight patients remain on the study for continued treatment, receiving an additional dose of TTX-MC138 during each 28-day treatment cycle, and may remain on the study absent any significant safety observations or disease progression.Also Read: Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints. Ongoing analyses of PK activity from Cohorts 1, 2, and 3 suggest that TTX-MC138 demonstrates a PK/PD profile consistent with preclinical results and results from TransCode's Phase 0 clinical trial.The observed tolerability profile and the available PK/PD results thus far support the advancement of the clinical trial to evaluate the saf","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exclusive-transcode-therapeutics-reports-progress-123230730.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4139","RNAZ","LENZ","BK4539","PRGS","SSI","BK4097","LU2065732104.USD"],"gpt_icon":0},{"id":"2532707409","title":"Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2532707409","media":"Newsfile","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532707409?lang=en_us&edition=fundamental","pubTime":"2025-05-01 20:30","pubTimestamp":1746102600,"startTime":"0","endTime":"0","summary":"Alpharetta, Georgia-- - Dogwood Therapeutics, Inc. , today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.Greg Duncan, CEO and Chairman, will be hosting one-on-one meetings on May 14th from 9:00 A.M. to 3:00 P.M. .To register for one-on-one meetings with management at The Plaza Hotel in New York City, interested parties should contact John Perez at jperez@dboralcapital.com.D. Boral Capital LLC is an investment bank headquartered in New York which provides advisory and financing solutions to middle market and emerging growth companies. The Company has a proven track record of offering strategic guidance to clients across the globe in any sector, with access to capital from the USA, Asia, Europe, Middle East, and Latin America.D. Boral Capital is a leader on Wall Street, having aggregated over $25 billion in capital across approximately 350 transactions through various product types.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/dogwood-therapeutics-inc-announces-participation-123000685.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dogwood-therapeutics-inc-announces-participation-123000685.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","ET","BK4588","BK4144","BK4581","DWTX","BK4590","BK4561","BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2532071755","title":"Press Release: Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2532071755","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532071755?lang=en_us&edition=fundamental","pubTime":"2025-05-01 20:13","pubTimestamp":1746101580,"startTime":"0","endTime":"0","summary":"Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025. Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its first quarter 2025 financial and operating results on Tuesday, May 13, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Tuesday, May 13, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2025 financial and operating results and to provide a business update.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LINE","TM","BK4099","BK4588","03160","BK4022","BK4604","BK4007","BK4224","BK4555","BK4232","LCTX","BK4585","LENZ","R"],"gpt_icon":0},{"id":"2532807177","title":"Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2532807177","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532807177?lang=en_us&edition=fundamental","pubTime":"2025-05-01 20:00","pubTimestamp":1746100800,"startTime":"0","endTime":"0","summary":"BASKING RIDGE, N.J., May 01, 2025  -- Lisata Therapeutics, Inc.  , a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the three months ended March 31, 2025, on Thursday, May 8, 2025, after the close of trading and will host a conference call at 4:30 p.m. Eastern time.Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call details with dial-in options. To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time.A live webcast of the call will also be accessible under the Investors & News section of Lisata’s website and will be available for replay beginning two hours after the conclusion of the call for 12 months.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lisata-therapeutics-report-first-quarter-120000048.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4007","BK4139","LSTA"],"gpt_icon":0},{"id":"2532071275","title":"Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology","url":"https://stock-news.laohu8.com/highlight/detail?id=2532071275","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532071275?lang=en_us&edition=fundamental","pubTime":"2025-05-01 20:00","pubTimestamp":1746100800,"startTime":"0","endTime":"0","summary":"BOSTON, May 01, 2025----Astria Therapeutics, Inc. , a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that results from a Phase 1a trial in healthy subjects supporting navenibart’s potential to provide long-acting, safe, and effective attack prevention for hereditary angioedema  with dosing every 3 and 6 months have been published in the Annals of Allergy, Asthma & Immunology.\"We are thrilled by our publication in the Annals of Allergy, Asthma & Immunology and the opportunity to provide additional information that affirms our belief in navenibart’s potential to become the first-choice therapy for HAE,\" said Christopher Morabito, M.D., Chief Medical Officer at Astria Therapeutics. \"The Phase 1a trial in healthy subjects laid the foundation for the advancement of navenibart and charted a path toward initiating ALPHA-ORBIT, our currently enrolling pivotal Phase 3 trial. The Phase 3 program, designed to introduc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astria-therapeutics-announces-publication-navenibart-120000006.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4198","LU0012050646.USD","ATXS","LENZ","LU0205194284.USD","HAE","IE00B64QTZ34.USD","LU0205193047.USD","LU1169590202.USD","IE00BLDYK493.USD","BK4007","LU0106261612.USD","LU1169589451.USD"],"gpt_icon":0},{"id":"2532018074","title":"Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2532018074","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532018074?lang=en_us&edition=fundamental","pubTime":"2025-05-01 20:00","pubTimestamp":1746100800,"startTime":"0","endTime":"0","summary":"Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025. CARLSBAD, Calif., May 01, 2025  -- Design Therapeutics, Inc. , a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced favorable data from a Phase 1 single- and multiple-ascending dose  trial of DT-168 in healthy volunteers, which will be presented on May 2, 2025 at Eyecelerator @ Park City 2025, an event backed by the American Academy of Ophthalmology highlighting industry advancements and innovative new products disrupting eye care.Based on these findings, Design plans to conduct a Phase 2 biomarker trial of DT-168 to evaluate safety, tolerability, and corneal endothelium biomarkers in patients with FECD. The trial will enroll FECD patients with the TCF4 mutation who are sc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/design-therapeutics-announces-favorable-phase-120000674.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4539","DSGN","BK4505","LENZ","BK4181","BK4218","BK4139","PK"],"gpt_icon":0},{"id":"2532307692","title":"Bicycle Therapeutics Q1 EPS $(0.88) Misses $(0.86) Estimate, Collaboration Revenue $9.98M Beat $7.78M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2532307692","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532307692?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:45","pubTimestamp":1746099912,"startTime":"0","endTime":"0","summary":"Bicycle Therapeutics Q1 EPS $(0.88) Misses $(0.86) Estimate, Collaboration Revenue $9.98M Beat $7.78M Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45131820/bicycle-therapeutics-q1-eps-0-88-misses-0-86-estimate-collaboration-revenue-9-98m-beat-7-78m-estima","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BCYC"],"gpt_icon":0},{"id":"2532740080","title":"Gain Therapeutics to Participate at The Citizens Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2532740080","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532740080?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:30","pubTimestamp":1746099000,"startTime":"0","endTime":"0","summary":"BETHESDA, Md., May 01, 2025  -- Gain Therapeutics, Inc.  , a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO of Gain, will present and participate in one-on-one meetings at The Citizens Life Sciences Conference, being held May 7th-8th in New York City, NY.Please contact your representative at Citizens if you would like to set up a one-on-one meeting with management.About Gain Therapeutics, Inc.Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a Phase 1b clinical trial. GT-02287 has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Gain has multiple undisclosed preclinical as","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gain-therapeutics-participate-citizens-life-113000327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GANX","BK4007","BK4139","LENZ"],"gpt_icon":0},{"id":"2532900079","title":"Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2532900079","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532900079?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:00","pubTimestamp":1746097200,"startTime":"0","endTime":"0","summary":"Multiple abstracts accepted for presentation at 2025 ASCO and AACR annual meetings underscore breadth of Bicycle technology and potential of oncology pipeline. Phase 1/2 Duravelo-3 trial for zelenectide pevedotin in NECTIN4-amplified breast cancer open and actively recruiting patients. Bolstered business and clinical expertise with appointments to Board of Directors, Clinical Advisory Board and company management team. Cash and cash equivalents of $793.0 million as of March 31, 2025, with expected financial runway into 2H 2027. CAMBRIDGE, England & BOSTON, May 01, 2025----Bicycle Therapeutics plc , a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide  technology, today reported recent business progress and financial results for the first quarter ended March 31, 2025.Two abstracts accepted for poster presentation at the 2025 American Society for Clinical Oncology  Annual Meeting. Bicycle Therapeutics will present tw","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bicycle-therapeutics-reports-recent-business-110000644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065732104.USD","BK4007","BK4139","BCYC","PRGS","LENZ","BK4097"],"gpt_icon":0},{"id":"2532708910","title":"Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2532708910","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532708910?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:00","pubTimestamp":1746097200,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass. & MONTREAL, May 01, 2025----Repare Therapeutics Inc.  , a leading clinical-stage precision oncology company, today announced that it has out-licensed its discovery platforms, including certain platform and program intellectual property, to DCx Biotherapeutics Corporation , a newly-launched Canadian biotechnology company developing next generation precision drug conjugates and supported by Amplitude Ventures. Additionally, DCx will retain certain preclinical research personnel, acquire lease rights to certain laboratory facilities in Montreal and acquire certain laboratory equipment.Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare has utilized its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Repare’s clini","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/repare-therapeutics-announces-licensing-discovery-110000323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","RPTX","LENZ","BK4007"],"gpt_icon":0},{"id":"2532168078","title":"Press Release: Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2532168078","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532168078?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:00","pubTimestamp":1746097200,"startTime":"0","endTime":"0","summary":"BOSTON, May 01, 2025  -- Tango Therapeutics, Inc. , today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call.Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","TNGX","BK4007","BK4139"],"gpt_icon":0},{"id":"2532078248","title":"Press Release: Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2532078248","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532078248?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:00","pubTimestamp":1746097200,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., May 01, 2025  -- Foghorn Therapeutics Inc. , a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Neil Gallagher, M.D., Ph.D., and Stuart Duty, to its Board of Directors.\"Neil and Stuart are experienced leaders with decades of deep and multifaceted understanding of the biotechnology industry,\" said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. \"We are pleased to welcome them to our Board of Directors and will leverage their strategic insights as we further advance our pipeline.\". Stuart Duty brings over 30 years of experience in finance and investment banking in biotechnology and specialty pharmaceuticals. Most recently, he served as a Senior Managing Director at Guggenheim Securities, LLC where he advised senior executives and boards on a range of financing activities and strategic transactions. Previously, he held senior ro","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4022","BK4139","LENZ","BK4232","BK4007","FHTX"],"gpt_icon":0}],"pageSize":20,"totalPage":14,"pageCount":6,"totalSize":274,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-05-08","symbol":"LENZ","fiscalQuarterEnding":"2024/03","expectedEps":-0.84,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"pre","actualEps":-3.53},{"market":"US","date":"2024-03-22","symbol":"LENZ","defaultRemindTime":1711114200000,"type":"split","dateTimestamp":1711080000000,"forFactor":7,"toFactor":1,"ratio":7},{"date":"2024-03-22","symbol":"LENZ","amount":1.03,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-18","name":"Therapeutics","recordDate":"2024-03-21","payableDate":"2024-03-18","currency":"USD","dateTimestamp":1711080000000,"payDate":"2024-03-21"},{"market":"US","date":"2021-08-12","symbol":"LENZ","fiscalQuarterEnding":"2021/06","expectedEps":-1.11,"name":null,"time":"","type":"earning","dateTimestamp":1628740800000,"reportTimeType":"","actualEps":-3.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":8,"updateTime":1742270400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2025-05-06","current":-16.104499,"percent":0.042308,"low":-16.900596,"twenty":-14.006194,"median":-10.013323,"eighty":-6.443526,"high":-5.069183,"avg":-10.226866,"sd":3.303504,"marketCap":801504792},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-06","current":-16.104499,"twenty":-14.006194,"median":-10.013323,"eighty":-6.443526,"marketCap":801504792}],"updateTime":1746637479715}}}